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Laboratory investigations in obstetrics and gynaecology prac-
tice have much in common with those in other medical disci-
plines. However, there is a range of laboratory tests which are
requested more frequently and one should be familiar with
these ‘panels’.  Patients with a family history or past history of
various medical conditions, or those with complications on
presentation, will obviously require specific and additional lab-
oratory tests which must be discussed with the relevant patholo-
gist and gynaecologist.
TESTS COMMON TO ALL DISCIPLINES
• Full blood count





• Vitamin B12 and folate
• Iron profile
• Thyroid function
• HIV diagnosis and monitoring. 
These ‘universal’ tests are often requested as screening labora-
tory tests in asymptomatic patients. The advantages lie in the
ability to detect asymptomatic abnormalities.  The choice will
depend on various factors, e.g. age, risk profile, dietary histo-
ry, associated diseases and current therapy.
ROUTINE LABORATORY TESTS IN OBSTETRICS
• Pregnancy tests
• Full blood count
• Rubella
• Blood groups
• Rapid plasma reagin (for syphilis)
• Hepatitis B
• HIV
• Alpha fetoprotein and Down’s screen (α-fetoprotein, β-human
chorionic gonadotrophin (HCG) and unconjugated oestriol)
• Glucose tolerance test
• Midstream urine
• Papanicolaou cervical smear. 
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It is sometimes difficult to know which laboratory tests are necessary and then how to
interpret them.  
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Pregnancy tests
The biochemical diagnosis of early
pregnancy is now taken for granted
with the advent of the monoclonal anti-
body technique. There are numerous
rapid home kits that detect HCG in
urine or whole blood.  Few practition-
ers are aware that only four decades
ago the test was based on injecting a
patient’s urine into frogs and noting its
effects on egg or sperm production
stimulated by the presence of HCG in
the sample.
The current assays have excellent sen-
sitivities and specificities for HCG.
However, it is recommended that these
rapid tests have both positive and neg-
ative controls incorporated in the
assay. Serum-based laboratory tests
for HCG have the advantage of offer-
ing quantitative levels (usually at the
same cost to the patient as a qualita-
tive test) and the option of performing
additional assays (e.g. progesterone,
follicle-stimulating hormone (FSH), 




Apart from an altered physiological
state in pregnancy characterised by
an expanded plasma volume and
reduced blood haemoglobin concen-
tration manifesting as a normochromic
normocytic anaemia, the mother is at
greater risk of a nutritional anaemia of
especially iron (microcytic anaemia)
and folate (macrocytic anaemia).
Other incidental findings on routine
antenatal full blood count screening
could include, for example, a thalas-
saemia or sickle cell trait or hereditary
spherocytosis.  Later in pregnancy a
haemolytic anaemia may be found in
pre-eclamptic and eclamptic mothers
as part of the HELLP syndrome
(Haemolysis, Elevated Liver enzymes
and Low Platelets).
Antenatal blood group and
irregular antibody screening
ABO and rhesus grouping can be
readily obtained if not already known.
A pregnant rhesus-negative woman
needs regular testing throughout the
pregnancy either to monitor the titre of
a known irregular antibody (commonly
anti-D) or to detect the development of
an irregular antibody.
A screen for irregular antibodies in
those who are rhesus positive can also
be of value in detecting obstetrically




Although not always possible, the
ideal time to assess and manage
potential pregnancy complications is
in the preconception period.
Prevention of infections during preg-
nancy is important for both the mother
and the developing fetus.  
Available vaccines that should be con-
sidered include measles, mumps,
rubella, varicella and hepatitis B.
Mumps in the first trimester may be
associated with fetal death, while
measles may lead to preterm birth and
possible miscarriage. The congenital
rubella syndrome (deafness, cataracts,
cardiac defects and mental retarda-
tion) may occur in 20 - 85% of infants
in women with rubella during the first
trimester.  Vaccines are best adminis-
tered before conception.  In addition,
preconception treatment of HIV, tuber-
culosis, Neisseria gonorrhoeae,
Chlamydia trachomatis and
Treponema pallidum will help to
decrease complications during preg-
nancy.  Screening for cytomegalovirus
and toxoplasmosis may also be indi-
cated to avoid risk factors in specific
settings.
Prenatal screening
The following are considered basic
antenatal tests:
Urine culture
Asymptomatic bacteriuria — defined
as the presence of more than 
100 000 colony-forming units (>105
CfU) per ml of urine in the absence of
urinary symptoms — occurs in 6 - 7%
of pregnant women.  The significance
of this finding is that acute
pyelonephritis, with its associated com-
plication of poor pregnancy outcome,
occurs in 20 - 40% of pregnant
patients with untreated asymptomatic
bacteriuria.  It is estimated that a
reduction (4 - 0.8%) in pyelonephritis
in pregnancy can be achieved by a
policy of routine prenatal screening
with urine cultures and treatment of
asymptomatic bacteriuria.
Serological tests
• Rubella antibody titres
• Syphilis serology (RPR)
• Hepatitis B surface antigen
• HIV antibody (ELISA).
Alpha fetoprotein and
Down’s screening
Down’s screening is the commonest
prenatal genetic test requested.
Although the risk of trisomy 21
increases with increased maternal
age, 80% of all affected babies are
born to women under the age of 35
years.  The triple test (α-fetoprotein, 
β-HCG, unconjugated oestriol), ideally
performed between 16 and 18 weeks’
gestation (range 15 - 20 weeks), will
detect up to 70% of affected pregnan-
cies.  The major disadvantage of this
test is the high number of false posi-
tives, which lead to uneccessary
amniocenteses.  The α-fetoprotein com-
ponent of the test will provide informa-
tion on the risk of neural tube defects
(NTDs).
Recently, screening even earlier in
pregnancy (10 - 13 weeks and 6
days) has become possible with the
first trimester screening programme
(free β-HCG and pregnancy-associated
plasma protein A).  The sensitivity and
specificity of the test are improved
dramatically with ultrasonographic
measurement of the nuchal translucen-
cy (a sonolucent space at the back of
the fetus’s neck in the first trimester)
and the identification of the nasal
bones.  Measurement of the nuchal
translucency is a very specific tech-
nique that was accredited by the Fetal
Medical Foundation prior to its inclu-
sion in the risk calculation programme.
Glucose tolerance tests
Approximately 7% of all pregnancies
are complicated by gestational 
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The biochemical diagnosis
of early pregnancy is now
taken for granted with the
advent of the monoclonal
antibody technique.
Other incidental findings
on routine antenatal full
blood count screening
could include, for example,
a thalassaemia or sickle
cell trait or hereditary
spherocytosis.
A pregnant rhesus-negative
woman needs regular test-
ing throughout the preg-
nancy either to monitor the
titre of a known irregular
antibody (commonly anti-D)
or to detect the develop-
ment of an irregular anti-
body.
diabetes mellitus (GDM) (prevalence
ranging from 1% to 14%, depending
on the population group and diagnos-
tic criteria).  Women with clinical char-
acteristics of a high risk for GDM
(obesity, history of GDM, glycosuria or
a family history of diabetes) should be
tested on presentation.  If initial
screening is normal, they should be
retested between 24 and 28 weeks of
gestation.  Women of average risk
should be tested at 24 - 28 weeks’
gestation. A fasting glucose level of 
> 7.0 mmol/l or a random glucose of
> 11.0 mmol/l confirmed on a subse-
quent day is sufficient for the diagno-
sis of diabetes. A glucose tolerance
test is not necessary in this setting.
There are various protocols for glucose
loading, which include a 50 g glucose
challenge followed by a plasma glu-
cose level 1 hour later.  This can be
performed on non-fasted subjects and
will identify 80% of GDM patients,
who are subsequently tested by a 
formal oral glucose tolerance test
(OGTT).
The formal OGTT protocols include a
75 g or 100 g loading test with sam-
pling intervals ending at 2 or 3 hours
post challenge.  The cut-off at 2 hours
using either the 75 g or 100 g load is
8.6 mmol/l, which differs significantly
from that in the non-pregnant patient.
ROUTINE TESTS IN
GYNAECOLOGY
Of the panel of hormonal assays,
many tests are common for more than
one gynaecological disorder; howev-














Mid-luteal progesterone, LH, oestradi-
ol.
TSH/T4
The advent of ultrasensitive TSH
assays has enabled screening of thy-
roid disease by a single test.  Raised
levels require evaluation of hypothy-
roidism (free T4, thyroid antibodies)
and suppressed levels suggest thyro-
toxicosis (free T4, free T3, thyroid anti-
bodies).
In patients in whom Sheehan’s syn-
drome (pituitary disorder) is suspected,
the TSH is of no value; a free T4 level
is a better indicator of the hypothy-
roidism.
Gonadotrophins (FSH, LH)
These levels vary during the menstrual
cycle and ideally should be assessed
on day 3 of the cycle.  The interpreta-
tion of the levels must take cognisance
of the phase in the cycle. Gonado-
trophins should not be measured if
patients are taking the contraceptive
pill or medroxyprogesterone acetate
(Provera), as levels will be suppressed.
Another common case for suppressed
levels is early pregnancy.
FSH levels > 20 mIU/ml are consistent
with a perimenopausal state and
should be assessed with the clinical
history.
The LH:FSH in polycystic ovarian syn-
drome of greater than 2 must not be
confused with the pre-ovulatory LH
surge at mid-cycle. The oestradiol level
on the same sample will help distin-
guish the conditions.
Androgen profile
This is usually reserved for patients
with hirsutism, severe acne, or virilis-
ing features. Family history, menstrual
abnormalities and rate of development
of signs and symptoms will dictate the
extent of investigations.  The current
profile will assist in identifying the
source of androgens (ovary or adre-
nal).
Fasting insulin, glucose
Insulin resistance is associated with
polycystic ovarian disease (PCOD)
(also with obesity, some
endocrinopathies, early diabetes), and
therapy with metformin has improved
menstrual and ovulatory function in
most of these patients.
Ovulatory tests: progesterone
In a 28-day cycle, the day 21 proges-
terone level will indicate whether ovu-
lation occurred in that cycle.  To iden-
tify ovulation biochemically during the
cycle (as opposed to after the event),
serial LH and oestrodiol levels should
be determined.
Prolactin
Raised prolactin levels with or without
galactorrhoea may be associated with
infertility and menstrual abnormalities.
Galactorrhoea with normal prolactin
levels indicates increased breast tissue
sensitivity to the hormone, and imag-
ing of the pituitary gland is not neces-
sary.  Causes of raised prolactin
include stress, physical examination,
therapy, hypothyroidism, macropro-
lactinaemia, and hypothalamic-
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pituitary pathology. A raised level
must be confirmed on repeat testing in
a non-stressed state.
Future investigations
Genetic tests for carrier status of vari-
ous abnormalities are currently avail-
able (cystic fibrosis, haemoglo-
binopathies, Tay-Sachs, Gaucher’s,
haemochromatosis). As the range
expands, there will be increased pres-
sure on the practitioner for screening.
Techniques are available for separa-
tion of fetal cells from maternal blood;
the potential will soon arise to perform
genetic testing directly on fetal cells,
with minimal invasiveness.
CONCLUSION
Laboratory tests play an important role
in obstetrics and gynaecology, as in
any other discipline of medicine. Their
role in antenatal screening is of partic-
ular relevance because many women
in poor countries are attended to by
health professionals for the first time in
their lives during the first pregnancy.
In the face of increasing cost-contain-
ment pressures from managed care
measures, the practitioner must bal-
ance this against the benefits of the
various preclinical diagnostic tests
available.
For more information on laboratory
tests: www.labtestsonline.org
Knowledge of laboratory tests is critical to clinical management. 
Preconception and antenatal screening is essential.
Reproductive hormonal levels are influenced by factors such as stage of cycle, maternal age and therapy.
IN A NUTSHELL
PATIENTS WITH PERIPHERAL VASCULAR
DISEASE UNDERESTIMATE THEIR RISK OF
CARDIAC DISEASE
This interesting paper compared patients' perceptions of
their risk of cardiovascular disease (CVD) and the benefits
of CVD risk factor reduction between patients with peripher-
al arterial disease (PAD), patients with coronary artery dis-
ease (CAD) and patients with no disease. All groups report-
ed that the risks of myocardial infarction, stroke and death
were higher for a patient with CAD than for a patient with
PAD.
Compared with other patients, those with PAD underestimat-
ed the high risk of cardiovascular events associated with
PAD and the benefits of cholesterol-lowering therapy. This
may help to explain the low rates of CVD risk factor control
previously reported in patients with PAD. 
It would probably help if the attending doctor explained
that all vessels start with the heart, and that if the peripher-
al vessels are damaged, there is a good chance that those
in the heart are also not too healthy.
McGrae M, et al. Arch Intern Med 2003: 163: 2157-2162.
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